Current Overview of Anti-Tuberculosis Drugs: Metabolism and Toxicities

Overview and management of toxicities of immune checkpoint-blocking drugs

Emerging evidence supports a vital role of the endogenous immune response system in the recognition, control and elimination of malignant cells. In the early phases of cancer development, molecular alterations caused by the tumour trigger the development of tumour-associated antigens (TAAs), which are initially recognised by the immune system. During tumour evolution, accumulation of genetic mu...

STUDY ON THE HEPATOTOXICITY OF ANTI-TUBERCULOSIS DRUGS IN 190 PATIE NTS WITH PULMONARY AND E XTRAPULMONARY TUBERCULOSIS

Tuberculosis is one of the oldest diseases that affects humans. The cause of this disease is Mycobacterium tuberculosis. This disease affects approximately 8.8 million people worldwide and led to over 3 million deaths in 1995. 95% of those affected and 98% of deaths occurred in developing countries. Hepatic reactions constitute a major proportion of drug reactions to antituberculosis drugs ...

drug-resistant tuberculosis and group 5 anti-tuberculosis drugs

Anti-tuberculosis drugs and liver toxicity.

Clinical development of anti-tuberculosis drugs.

In the clinical development of new anti-tuberculosis drugs, the most important step is efficient Phase II studies to show whether the drug is likely to be able to shorten treatment and with what other drugs it has the greatest sterilizing activity. The use of non-linear mixed effects modelling applied to serial sputum cfu counts appears to be the most effective technique, but we know little abo...